Biomarkers and translational research and precision medicine

46P - BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience

Authors
  • Eleonora Molinaro (Modena, Italy)
  • Marta Venturelli (Modena, Italy)
  • Angela Toss (Modena, Italy)
  • Claudia Piombino (Modena, Italy)
  • Elena Barbieri (Modena, Italy)
  • Luigi Marcheselli (Modena, Italy)
  • Isabella Marchi (Modena, Italy)
  • Enrico Tagliafico (Modena, Italy)
  • Stefano Cascinu (Modena, Italy)
  • Laura Cortesi (Modena, Italy)
Speakers
  • Eleonora Molinaro (Modena, Italy)

Previous ePoster
43P - CIP2A as a novel target to combat basal like breast cancer

Next ePosters
49P - The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms
50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy
51P - Higher ER load is not associated with better outcome in stage I-III breast cancer
52P - The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC
53P - Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients
54P - Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab
55P - Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome
58P - Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers
59P - Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients
60P - Anti-inflammatory treatment and inhibition of B-cell activation in a nude mouse model of human breast cancer